虚血性脳卒中市場レポート：2030年までの動向、予測、競合分析

虚血性脳卒中の動向と予測

世界の虚血性脳卒中市場は、2024年から2030年までのCAGRが7.5%で、2030年までに推定71億8,000万米ドルに達すると予測されます。この市場の主な促進要因は、人々の健康意識の高まり、世界の糖尿病率の上昇、タバコ使用者の増加です。世界の虚血性脳卒中市場は、CT、MRI、頸動脈超音波検査、脳血管撮影の各市場におけるビジネスチャンスにより、将来が有望視されています。

セグメント別虚血性脳卒中

世界の虚血性脳卒中の診断、薬剤クラス別、地域別の予測を掲載しています。

虚血性脳卒中関連企業リスト

市場に参入している企業は、提供する製品の品質に基づいて競争しています。この市場の主要企業は、製造施設の拡大、研究開発投資、インフラ開拓、バリューチェーン全体にわたる統合機会の活用に注力しています。これらの戦略により、虚血性脳卒中企業は需要の増加に対応し、競争力を確保し、革新的な製品と技術を開発し、製造コストを削減し、顧客基盤を拡大しています。本レポートで紹介する虚血性脳卒中企業は以下の通りです。

• アボット・ラボラトリーズ
• バイエル
• ベーリンガーインゲルハイム
• ボストン・サイエンティフィック社
• コーディス・コーポレーション
• コヴィディエン
• GEヘルスケア
• ジェネンテック
• ジョンソン・エンド・ジョンソン
• フィリップスN.V.
• メドトロニック

虚血性脳卒中サノフィ

• Lucintelの予測では、抗血小板薬は血栓形成を予防し、その後の脳卒中のリスクを最小限に抑えるため、虚血性脳卒中の第一選択薬として使用されるため、予測期間中も最大セグメントであり続ける。
• CTは、所要時間が短く、脳の解剖学的構造を詳細に見ることができるため、最大セグメントであり続けると思われます。
• 予測期間中、北米が最大セグメントであり続けるのは、同地域における政府の好意的な取り組みと継続的な技術進歩によるものです。

本レポートでは、以下の11の主要な質問に回答している：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の虚血性脳卒中市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の虚血性脳卒中市場の動向（2018～2023年）と予測（2024～2030年）
• 診断別の世界の虚血性脳卒中市場
  • CT
  • MRI
  • 頸動脈超音波検査
  • 脳血管造影
• 薬剤クラス別の世界の虚血性脳卒中市場
  • 組織プラスミノーゲン活性化因子
  • 抗凝固剤
  • 抗血小板
  • 降圧剤

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界の虚血性脳卒中市場
• 北米の虚血性脳卒中市場
• 欧州の虚血性脳卒中市場
• アジア太平洋虚血性脳卒中市場
• その他地域虚血性脳卒中市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • 診断による世界の虚血性脳卒中市場の成長機会
  • 薬剤クラス別の世界の虚血性脳卒中市場の成長機会
  • 地域別の世界の虚血性脳卒中市場の成長機会
• 世界の虚血性脳卒中市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の虚血性脳卒中市場の能力拡大
  • 世界の虚血性脳卒中市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Abott Laboratories
• Bayer
• Boehringer Ingelheim
• Boston Scientific Corporation
• Cordis Corporation
• Covidien
• GE Healthcare
• Genentech
• Johnson & Johnson
• Koninklijke Philips N.V.

Ischemic Stroke Trends and Forecast

The future of the global ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets. The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030 with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.

A more than 150-page report is developed to help in your business decisions.

Ischemic Stroke by Segment

The study includes a forecast for the global ischemic stroke by diagnosis, drug class, and region.

Ischemic Stroke Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

• CT
• MRI
• Carotid Ultrasounds
• Cerebral Angiography

Ischemic Stroke Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

• Tissue Plasminogen Activator
• Anticoagulant
• Antiplatelet
• Antihypertensive

Ischemic Stroke Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Ischemic Stroke Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ischemic stroke companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ischemic stroke companies profiled in this report include-

• Abbott Laboratories
• Bayer
• Boehringer Ingelheim
• Boston Scientific Corporation
• Cordis Corporation
• Covidien
• GE Healthcare
• Genentech
• Johnson & Johnson
• Koninklijke Philips N.V.
• Medtronic

Ischemic Stroke Sanofi

• Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.

• CT will remain the largest segment because it ensures short turnaround time and ability to see the brain anatomy in detail.

• North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.

Features of the Global Ischemic Stroke Market

• Market Size Estimates: Ischemic stroke market size estimation in terms of value ($B).

• Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

• Segmentation Analysis: Ischemic stroke market size by diagnosis, drug class, and region. in terms of value ($B).

• Regional Analysis: Ischemic stroke market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

• Growth Opportunities: Analysis of growth opportunities in different diagnosis, drug class, and region.s for the ischemic stroke market.

• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ischemic stroke market.

• Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the ischemic stroke market size?

Answer: The global ischemic stroke market is expected to reach an estimated $7.18 billion by 2030.

Q.2. What is the growth forecast for ischemic stroke market?

Answer: The global ischemic stroke market is expected to grow with a CAGR of 7.5% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the ischemic stroke market?

Answer: The major drivers for this market are increased health awareness among people, rising diabetes rates across the globe, and growing number of tobacco users.

Q.4. What are the major segments for ischemic stroke market?

Answer: The future of the ischemic stroke market looks promising with opportunities in the CT, MRI, carotid ultrasounds, and cerebral angiography markets.

Q.5. Who are the key Ischemic Stroke Market companies?

Answer: Some of the key ischemic stroke companies are as follows:

• Abbott Laboratories
• Bayer
• Boehringer Ingelheim
• Boston Scientific Corporation
• Cordis Corporation
• Covidien
• GE Healthcare
• Genentech
• Johnson & Johnson
• Koninklijke Philips N.V.

Q.6. Which ischemic stroke market segment will be the largest in future?

Answer: Lucintel forecasts that antiplatelet will remain the largest segment over the forecast period as it is used as a first-line treatment for ischemic stroke since they help prevent blood clot formation and minimize the risk of subsequent strokes.

Q.7. In ischemic stroke market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to favorable government initiatives and on-going technological advancements in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the ischemic stroke market by diagnosis (CT, MRI, carotid ultrasounds, and cerebral angiography), drug class (tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Ischemic Stroke Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Ischemic Stroke Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Ischemic Stroke Market by Diagnosis
  • 3.3.1: CT
  • 3.3.2: MRI
  • 3.3.3: Carotid Ultrasounds
  • 3.3.4: Cerebral Angiography
• 3.4: Global Ischemic Stroke Market by Drug Class
  • 3.4.1: Tissue Plasminogen Activator
  • 3.4.2: Anticoagulant
  • 3.4.3: Antiplatelet
  • 3.4.4: Antihypertensive

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Ischemic Stroke Market by Region
• 4.2: North American Ischemic Stroke Market
  • 4.2.2: North American Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
• 4.3: European Ischemic Stroke Market
  • 4.3.1: European Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
  • 4.3.2: European Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
• 4.4: APAC Ischemic Stroke Market
  • 4.4.1: APAC Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
  • 4.4.2: APAC Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive
• 4.5: ROW Ischemic Stroke Market
  • 4.5.1: ROW Ischemic Stroke Market by Diagnosis: CT, MRI, Carotid Ultrasounds, and Cerebral Angiography
  • 4.5.2: ROW Ischemic Stroke Market by Drug Class: Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Ischemic Stroke Market by Diagnosis
  • 6.1.2: Growth Opportunities for the Global Ischemic Stroke Market by Drug Class
  • 6.1.3: Growth Opportunities for the Global Ischemic Stroke Market by Region
• 6.2: Emerging Trends in the Global Ischemic Stroke Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Ischemic Stroke Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ischemic Stroke Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abott Laboratories
• 7.2: Bayer
• 7.3: Boehringer Ingelheim
• 7.4: Boston Scientific Corporation
• 7.5: Cordis Corporation
• 7.6: Covidien
• 7.7: GE Healthcare
• 7.8: Genentech
• 7.9: Johnson & Johnson
• 7.10: Koninklijke Philips N.V.